Acumen Pharmaceuticals (ABOS) Other Non Operating Income (2021 - 2026)
Acumen Pharmaceuticals (ABOS) posted Other Non Operating Income of $460000.0 for Q1 2026, up 332.32% sequentially from -$198000.0 in Q4 2025, and up 142.11% YoY from $190000.0 in Q1 2025.
Acumen Pharmaceuticals (ABOS) Other Non Operating Income (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Other Non Operating Income for 6 years, with the latest figure at $460000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 142.11% year-over-year to $460000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153000.0 (up 114.18% YoY) and the FY2025 annual result came in at -$460000.0, down 204.64% from the prior year.
- Other Non Operating Income rose to $460000.0 in Q1 2026 per ABOS's latest filing, from -$198000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $460000.0 in Q1 2026 and troughed at -$1.2 million in Q4 2024.
- A 5-year average of -$72571.4 and a median of -$15500.0 in 2022 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income slumped 5571.43% in 2024, then surged 451.85% in 2025.
- Over 5 years, Other Non Operating Income stood at -$10000.0 in 2022, then tumbled by 110.0% to -$21000.0 in 2023, then plunged by 5571.43% to -$1.2 million in 2024, then soared by 83.38% to -$198000.0 in 2025, then surged by 332.32% to $460000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $460000.0, -$198000.0, and -$69000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -160,000.00 |
| Mar 31, 2026 | 460,000.00 |
| Dec 31, 2025 | -198,000.00 |
| Sep 30, 2025 | -69,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | 190,000.00 |
| Dec 31, 2024 | -1.19 Mn |
| Sep 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -68,000.00 |
| Mar 31, 2024 | -54,000.00 |
| Dec 31, 2023 | -21,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | -10,000.00 |
| Sep 30, 2022 | -2,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 19,000.00 |
| Jun 30, 2021 | 19,000.00 |
| Mar 31, 2021 | 9,000.00 |